Compare NLOP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NLOP | WHWK |
|---|---|---|
| Founded | N/A | 2007 |
| Country | United States | United States |
| Employees | N/A | 23 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 198.4M | 196.3M |
| IPO Year | 2022 | N/A |
| Metric | NLOP | WHWK |
|---|---|---|
| Price | $13.22 | $4.19 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 173.9K | ★ 223.9K |
| Earning Date | 05-19-2026 | 05-06-2026 |
| Dividend Yield | ★ 51.10% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $118,915,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.24 | $1.44 |
| 52 Week High | $34.53 | $4.40 |
| Indicator | NLOP | WHWK |
|---|---|---|
| Relative Strength Index (RSI) | 53.24 | 61.28 |
| Support Level | $12.76 | $1.84 |
| Resistance Level | $14.70 | $4.40 |
| Average True Range (ATR) | 0.28 | 0.30 |
| MACD | 0.24 | 0.02 |
| Stochastic Oscillator | 91.74 | 80.09 |
Net Lease Office Properties is a Maryland real estate investment trust that, together with its consolidated subsidiaries, owns a diversified portfolio of office properties that are primarily leased to corporate tenants on a single-tenant, net-lease basis. Its net leases generally specify a base rent with rent increases and require the tenant to pay substantially all costs associated with operating and maintaining the property. Its portfolio includes approximately 1.2 million square feet of Green-Certified Buildings, 2 LEED-certified buildings, and 1 BREEAM-certified building.
Whitehawk Therapeutics Inc is an oncology therapeutics company applying technologies to tumor biology to develop cancer treatments. Its portfolio includes three antibody-drug conjugate (ADC) candidates designed to address limitations of earlier therapies for patients with difficult-to-treat cancers. The company generates revenue from the sale of its products.